2022

 

09/27/2022

Xavo: When is it Time to Invest in Sample Management Software?

In this webinar, Xavo & 20/15 Visioneers will provide use cases and examples of when companies made the decision to invest in advanced sample and request management software. Typically, start-ups and younger biotechs manage their samples with Excel and SharePoint or even other paper-based approaches. High-level examples include increased sample load, collaborators, and overall company success.

Watch Recording Here

08/16/2022

Ukraine-Aid Webinar

20/15 Visioneers is sponsoring this event to provide a voice to our Ukrainian friends and family due to the recent war. This webinar will feature Ukrainian R&D and Healthcare companies.

Presenters


ChemSpace - Oleksii Gavrylenko, COO

Presentation Title: Delivering Discovery Solutions
 

Abstract: 

Founded back in 2015, Chemspace is a Ukrainian-based company with headquarters in Kyïv. We host the largest online catalog of Chemical and Biological Reagents provided by reliable Suppliers. Also, Chemspace provides Sourcing, Compound Management, and Hit Discovery Services. We collaborate with numerous suppliers who can fulfill custom requests to support our customers in their research projects. Our portfolio has been growing by adding products like Chemspace Freedom Space with hundreds of millions of synthesizable compounds, or services like an exploration of Enamine REAL Space utilizing the V-SYNTHES approach to screen billions of compounds fast and efficiently. All the above makes Chemspace a valuable partner to facilitate discovery.
 


DrugCards - Dmytro Horilyk, CEO
Presentation Title: How to Increase Revenue from PV Projects and Automate Medical Literature Monitoring?

 

Abstract:

[Coming Soon]

Enamine - Ivan Kondratrov, Head of Medicinal Chemistry
Presentation Title: Chemistry during the war: how Enamine Ltd adjusts and operates after February 24, 2022

Abstract:

Enamine Ltd is a world-known building block and chemical compound provider and a contract research organization (CRO). The company has more than 30 years of experience in wide range of chemistry and its products and services are important for plenty of early-stage Drug Discovery projects. The main facilities of the company are in Kyiv (Ukraine) and they became under threat once Russia started full-scale invasion. Enamine had to stop operating for six weeks and resumed the work in the beginning of April. As many other companies Enamine faces number of challenges under the circumstance of the war: restart of the safe and effective production workflow, organization of logistics, partial relocation etc. Nevertheless, the company continues to operate and fulfill their obligations to clients. Details about the role of the company, new challenges, steps, and decisions in the days of war will be presented during the webinar.



Pharmaxi - Yuriy Lebed, CEO
Presentation Title: How Did Ukrainian CRO Survive After COVID-19 and the Military Crisis. Takeouts for the Future

 

Abstract:

A small Ukrainian company (30+ employees) focused on clinical research has passed through several turbulences. Chances of failure have been high because of the small market size, long contractual process, and absence of investors who could support the company financially. Nevertheless, we successfully passed even through the military invasion. Pharmaxi is stable again, and you will know what has been done to prepare for a crisis. We will talk about the principles of how to make the company sustainable and well prepared for future turbulence. I hope our lessons learned will be helpful for other SMEs to make your company more stable and resilient.
 



SMO UCT (Site Management Organization - Unit of Clinical Trials) - Olya Barabash, Development Manager
Presentation Title: Work and Development in Conditions of War: Cooperation in Long-Term Vision

Abstract:

Team of the Ukrainian Contract Research Company SMO UCT presents information on the current situation in Ukraine, on the basis of which you will be able to consider the prospects for working with the clinical trials market in Ukraine at the present time and in the future. Information on the abilities of SMO UCT for companies interested in long-term cooperation and partnership is provided as well. The presented data will allow an objective assessment of perspectives of Ukrainian clinical trials market.

Watch Recording Here

08/11/2022

RCH Solutions & 20/15 Visioneers: The State of R&D IT: A Future-Forward Discussion for Optimizing a Modern Life Sciences Lab

In this webinar, life science technologists and innovators within the Bio-IT landscape for nearly 30 years, Phil Eschallier of RCH Solutions and John Conway of 20/15 Visioneers, will offer perspectives and commentary on the most important modernization opportunities and trends within R&D IT, and share steps your team can take today to run toward a future-forward lab environment.

Watch Recording Here

07/20/2022

Scilligence: HELM as Enabler of Unified Entity Registration System

The pharmaceutical industry has seen a dramatic evolution from traditional small molecule drugs to a wide variety of therapeutic modalities. The increased complexity of therapeutics (antibody-drug conjugates, siRNA, mRNA vaccines, and antisense gene therapy) has created an unmet need in the discovery science space. Legacy systems, initially designed for small molecule drug discovery, are no longer able to support cutting edge research and development efforts. In this talk, we will discuss how to bridge the gap between chemical-based small molecule informatics system and letter-based biologics system using HELM (Hierarchical Editing Language for Macromolecules) technology. We will discuss the importance of using standardized notation, as prescribed by the Pistoia Alliance and IUPAC, and the registration and secure sharing of HELM monomers for de novo structure identification of macromolecules. Finally, we will address some of the unique challenges and solutions which have been proposed for HELM implementation in both industry and academic environments.

Watch Recording Here

07/14/2022

Flywheel: FAIR-ifying Medical Imaging Data: Accelerating Large-Scale Data Initiatives

Digital transformation initiatives are now relying on the FAIR Data principles to accelerate drug design, clinical trials, and AI efforts. However, complex data, such as medical images, present additional challenges that require unique solutions. In this presentation, we will discuss the soup-to-nuts approach of implementing FAIR across large teams to improve R&D efficiency and project outcomes. We’ll also discuss tools for centralizing and standardizing curation of complex data to accelerate AI research.
 

Presenter:
Can Akgun, PhD
SVP of Business Development, Flywheel

Watch Recording Here

07/13/2022

Qmetrics Technologies: Is It Safe to Play Again? Understanding Post-Concussive Microtrauma

 

Traumatic brain injury in sports and non-sports related trauma has not benefitted until now from advanced imaging analysis and deep learning. In the past, patients or subjects have been diagnosed and or advised with little or no knowledge on healing or duration of healing needed. Qmetrics Technologies has spent the past 15 years perfecting TBI understanding through advanced MRI imaging analysis and deep learning. They have created a concussion index to assess concussion severity and when healing has occurred which can allow safer return to the game or activity.

Come watch and learn how the future of sports and non-sports related head trauma could benefit from deep learning and pragmatic approaches.

https://www.qmetricstech.com/

Watch Recording Here

06/22/2022

Elucidata, Atomwise, Altis Labs, & Cyclica Panel Discussion: Implementing ML in Biomolecular Research: Limitations and Opportunities 

Owing to the complexity of human biology, making precise and viable predictions can be incredibly difficult This is where ML techniques, step in. Coupled with a domain-aware understanding of the underlying data, machine learning can show incredible promise for distilling robust and reliable prognostic indicators of various health conditions.

However, ML should not be thought of as a magic wand. Not paying attention to quality of input data can lead to the development of unreliable models in clinical settings. And in the realm of biomedical research, where datasets are frequently small, iterating on data quality is critical. Collecting and labelling a large amount of training data is time-consuming and expensive, and not always a practical solution.

To put short, running a successful ML project requires a rigorous assessment of data as well as methodology. In this roundtable discussion, the panelists will discuss some advantages and caveats to applying ML in biomedical research projects and why adopting a data-centric approach goes a long way to generating accurate predictions, even with small amounts of training data.

 

Watch Recording Here

06/15/2022

Copyright Clearance Center Panel Discussion: Unlocking the Value of Scientific Literature: Success Stories from the Field

Whether you’re a Chemical, Materials, Consumer Packaged Goods, or a Life Sciences R&D Company, FAIR scientific literature is extremely important to the success of your organization. Making sure that diverse sets of teams and departments have access to the right content at the right time is not a simple task. There are efficient methods for accessing, managing, collaborating on, and disseminating scientific literature. Join this panel discussion to hear information management veterans from Janssen Pharmaceuticals-Supporting Role, Reckitt Benckiser, Syngenta, and CCC share stories of challenges they’ve faced – and how they’ve overcome them.

The panelists will touch on a variety of topics including using technology to simplify content access, building a culture of compliance, and engaging strategic stakeholders to promote collaboration.

Watch Recording Here

05/24/2022

Strateos & Evariste Technologies Webinar: How Evariste Technologies Leveraged Cloud Lab Automation-as-a-Service to Accelerate Cycle Times for Faster Drug Discovery

Conventional DMTA (Design, Make, Test & Analyze) cycles are plagued by manual workflows, inadequate scientist-to-scientist communication across labs, less-than-ideal data tracking, slow cycle times, and the capital expense of discovery programs. Strateos’ shortens DMTA cycle times by automating the design and synthesis of small molecules, in vitro cell based and biochemical assays, and analysis of results. This cloud automation platform enables scientists to work on multiple programs at the same time in parallel, greatly improving process efficiencies and shortening cycle times. Evariste Technologies was able to leverage the DMTA cycle with Strateos, specifically in the Design and Analysis phases, to produce candidate molecules. Evariste Technologies will discuss how their platform can expedite drug discovery by utilizing AI/ML, automated molecular design, modeling solutions, and Bayesian statistics.

Key Takeaways:
How Strateos’ unique cloud-accessible closed-loop system is demonstrating complete DMTA cycles in a handful of days, greatly outpacing the two to three weeks or longer timelines required by either conventional outsourcing methods or internal turn-around times


How process control,automation, monitoring, data capture and analysis was accomplished with via a single web interface
How AI/ML automated molecular design and custom modeling solutions create better candidate molecules faster than traditional drug discovery cycles

Watch Recording Here

04/07/2022

Elucidata Webinar: A Data-Centric Platform for Harmonized Biomolecular Data

The biomedical data landscape is fragmented, with isolated data sources and knowledge bases that employ different syntaxes, schemas, entity notations, and metadata standards. Formats vary based on the type of data generated (imaging, sequencing data, documents, EHR, Flow Cytometry, etc.), and data is often inconsistently labeled & devoid of context.

Therefore, despite the availability of data, scientists still face significant logistical and technical challenges when hosting, integrating, & analyzing heterogeneous data collected from a variety of sources. Additionally, these data may require exhaustive computational resources and a unified querying interface for processing and in-depth data exploration.

Elucidata’s Polly is a Data-Centric platform architected to treat data as the continual focus. It manages the entire lifecycle of a biomedical dataset - from ingestion & harmonization, processing & preparing the data for AI/ML and pushing to downstream applications. Polly allows scientists to aggregate data generated from public repositories and proprietary experiments on a centralized Enterprise OmixAtlas, and mine for novel associations from these diverse sources to enhance the quality of their hypotheses. In addition, scientists can leverage the following capabilities of an OmixAtlas on Polly, to enable data-driven research:

  • Model-assisted curation for harmonizing datasets with ontology-backed metadata and ensuring they conform to an in-house data model.

  • An SQL-based programmatic interface that allows complex querying

  • A scalable computational platform to analyze and visualize data.

  • API-based access to stream Ml-Ready data from an OmixAtlas to data warehouses, software, BI tools, etc.

Watch Recording Here

04/05/2022

Xavo Webinar: Request and Sample Management is the Backbone of Industrialized R&D Organizations

With latest trends in Life Sciences and especially Biopharma R&D, Request and Sample Management are becoming the backbone of any industrialized R&D operations. This webinar is looking at the impact of respective market and technology trends and introduces Xavo R3, an integrated Request & Sample Management Software platform that addresses the strategic problem to optimally fulfill changing demand for assays and materials based on available finite lab capacity and material inventory.

There is an accompanying white paper "Request and Sample Management is the Backbone of Industrialized R&D Organizations" which you can download here: xavo.com/white-paper

Watch Recording Here ​​

 

03/24/2022

BISC Global Webinar: Key Challenges of Data-centric QSP and ML/AI: Scope of Problems, When and How

The following talks are going to do a deep dive in PK/PD, Quantitative Systems Pharmacology, and AI/ML!!

Talk 1: 14:10 – 14:50 (ET), Presentation 30 min, Q&A 10 min
“Typical PK/PD data and translational modeling”
Dr. Michael Monine (Biogen)

Talk 2: 14:50 – 15:30 (ET), Presentation 30 min, Q&A 10 min
“Big Data-Enabled, Biomarker-Based, AI/ML-Guided Quantitative Systems Pharmacology Models for Pharmacometrics”
Prof. Murali Ramanathan (University at Buffalo)

Talk 3: 15:30 – 16:10 (ET), Presentation 30 min, Q&A 10 min
“The use of AI-driven platform for prediction of drug pharmacokinetics following transdermal administration”
Dr. Maksim Khotimchenko (VeriSIM Life Inc)

Talk 4: 16:10 – 16:50 (ET), Presentation 30 min, Q&A 10 min
“AI/ML for Reverse Engineering: application to polypharmacology and deconvolution of signaling pathways”
Dr. Alexander Lukyanov (BISC Global)

Panel discussion: 17:20 – 17:40 (ET)
Moderator: John Conway, CEO, 20/15 Visioneers

Watch Recording Here

03/08/22-03/09/22

World's First Microbiome & Multi-Omics Virtual Conference

Day 1: March 8th, 2022 [Morning]

Watch Recording Here

Day 1: March 8th, 2022 [Afternoon]

Watch Recording Here

Day 2: March 9th, 2022 [Morning & Afternoon]

Watch Recording Here

02/24/222022

Materials Science MEGA Webinar​

The Mega Materials Science Webinar is all about highlighting all of the great Material Science Informatics and Modeling/Simulation that's going on in the World! Material Sciences has the great promise of benefitting from the proper scientific informatics and in silico approaches. 

 

Come hear how the following companies are making a difference to the world of Material Science! BIOVIA (www.biovia.com), BISC Global (www.biscglobal.com), Citrine Informatics (www.citrine.io), Dotmatics (www.dotmatics.com), Perkin Elmer Informatics (https://perkinelmerinformatics.com/) and Uncountable (www.uncountable.com)

 

PRESENTATIONS:

 

Dr. Alexander Lukyanov: Scientific Director - BISC Global

Talk Title: "An application of digital twin concept and machine learning to the prediction of the effect of orientation on the shock response of an anisotropic composite materials and metals" 

 

Abstract 

An application of digital twin concept and machine learning to construct constitutive relationships for modeling of shock wave propagation in orthotropic composite materials is proposed for nonlinear explicit meshless transient large deformation computer codes (hydrocodes). An anisotropic equation of state (EOS) is used for the accurate extrapolation of high-pressure shock Hugoniot (anisotropic and isotropic) states to other thermodynamic (anisotropic and isotropic) states for a shocked carbon-fiber epoxy composite (CFC) of any symmetry. Using an anisotropic nonlinear continuum framework, generalized decomposition of a stress tensor, digital twin concept and machine learning, the shock waves propagation in CFC materials is modelled using meshless hydrocode. The developed framework can be used to optimize the development of composite materials structure. It can be used to view the status of the composite materials under impact loading conditions, which provides a way to project physical properties into the digital world. 

 

 

Will Tashman: Chief Revenue Officer - Uncountable

Talk Title: "How a Collaborative R&D Platform can replace spreadsheets and traditional LIMS solutions"

Abstract
While many organizations want to centralize their data and make better use of modern techniques like artificial intelligence & machine learning, it is still a struggle to move scientists off their formulating tool of choice - the spreadsheet. While spreadsheets are an amazing invention and easy to use, they are often unique for each individual or team within a company, prevent true collaboration, and lead to machine learning problems due to data quality & quantity concerns.

In this webinar, Uncountable’s Chief Revenue Officer Will Tashman will discuss the barriers to moving scientists off of spreadsheets, where traditional ELN and LIMS systems have fallen short in this goal, and the benefits of moving to a truly collaborative platform. Will leads customer relationships for Uncountable's platform, which is trusted by industry leaders like Cabot Corporation, Carbon, Beiersdorf and Behr Paint.

 

 

Greg Mulholland: CEO - Citrine Informatics

Talk Title: The Business and Scientific Value of AI-Guided Product Development

 

Abstract

Artificial Intelligence has valuable and promising applications in materials and chemicals product development; from supply chain and regulatory resilience, to improved customer responsiveness, to accelerated product development. However, materials and chemicals data is often sparse, noisy, and complex. In this webinar, Citrine Informatics’s CEO Greg Mulholland will share how the Citrine Platform helps materials and chemicals companies overcome these challenges and share some customer successes with AI-guided product development.  

 

Ben Bracke: Executive Director Product Marketing & David Gosalvez: Director, Cheminformatics Product Portfolio- PerkinElmer Informatics

Talk Title: Accelerating Materials Science Research Via Next-generation Data Management and Analytics

 

Abstract

Learn how the PerkinElmer Signals Platform can accelerate research and shorten product delivery by streamlining research data capture and integrating advanced analytics.  This presentation will highlight the flexibility and ease of use of the cloud-based Signals Notebook, in combination with the power of Signals Inventa visual and predictive analytics.

 

Max Petersen:  AVP, Chemicals & Materials Marketing - Dotmatics 

Talk Title: From Instruments to Insights: A Platform Approach to Lab Data Automation

 

Abstract

The ability to deliver innovative products to the marketplace is at the core of many chemicals and materials companies. One of the main obstacles in doing so are high R&D cost and long development timelines. As a promising solution, data-driven R&D has made its way on executive agendas. At the same time, the underlying IT infrastructure required to provision R&D data to these data-modeling initiatives is often overlooked and/or under resourced. Consequently, many initiatives that aim at implementing data-driven R&D are facing data accessibility challenges, including insufficient data quality, lack of data contextualization or incomplete data sets because of poor system adoption.     

 

The solution to this problem is a uniform platform approach that can directly ingest data from their point of creation and serve up these data to lab managers, scientists, or directly to data modeling tools. This approach is a departure from traditional R&D IT infrastructure designs, as it avoids compartmentalizing data in silos e.g., in LIMS, ELN, or SDMS databases. This is especially important for materials innovation, as workflows are highly variable and generated by scientists from multiple disciplines, leading to data aggregation and curation issues across data silos.     

 

Our unified, data-driven platform that allows for flexible configuration of workflows and roles that naturally contextualizes R&D data. This is paired with a set of scientific data intelligence capabilities, that spans data querying across inhomogeneous data sources, data analytics, and advanced scientific data visualization applications. The platform can operate in conjunction with other IT systems and data sources or as a standalone system that includes lab digitalization. This presentation reviews the general aspects of this approach and discusses various customer scenarios of digitalization efforts in the chemicals and materials space.   

 

Stephen Todd: Senior Strategy Specialist, Materials Science - BIOVIA

Talk Title: Accelerating R&D through Democratized Materials Modelling and Platform Collaboration

 

 

Watch Recording Here

02/03/2022

TetraScience: Why Biopharma Is Replatforming to The Cloud; Industry Survey

The 2022 State of Digital Lab Transformation in Biopharma Survey results indicate a strong case to replatform scientific data to the cloud  — with many industry leaders identifying the move as critical in order to improve scientific outcomes and accelerate discovery.

Join this webinar for insights into a critical initiative gaining momentum in biopharma, considerations that need to be considered when replatforming, and how improved, cloud-based data management enables biopharma organizations to:

 

  • Speed lab digitization initiatives and digital data strategies

  • Provide FAIR data to accelerate research and scientific outcomes

  • Adapt to continuously evolving business needs


Speakers:

  • Mike Tarselli, Ph.D., Chief Scientific Officer, TetraScience

  • Peter Henstock, Machine Learning & AI Technical Lead, Pfizer

  • Marshall Brickeen, Global Life Sciences Lead, AWS Marketplace

 

Watch Recording Here

01/26/2022

Zifo Mega LIMS Webinar Series #7: Change Management – What if I Do – What if I Don’t - Do it! Experience and Knowledge from Global and Local LIMS Projects

Zifo R&D Solutions and 20/15 Visioneers are announcing the Live Mega LIMS Webinar Series for 2021. In this approximately 14 webinar series we will bring you a highly educational overview webinar followed by topic-driven LIMS webinars.

Watch Recording Here

01/11/2022

Elucidata Webinar: Curating Biomedical Molecular Data

Biomedical molecular data is sourced from fragmented public sources as well as proprietary experiments, this makes staying on top of all relevant data hard. Additionally processing and harmonizing data is a challenge, this further impedes the use and utility of this data.

Elucidata enables R&D teams to work with ML-ready data. Elucidata's Curation-on-demand is an end-to-end solution for teams that want to leverage data to accelerate discovery

  • Aggregating data from fragmented sources

  • Processing and structuring data into an Enterprise Atlas

  • Curating metadata

  • Providing programmatic access

Watch Recording Here